Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PTPRC | P08575 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL756932 | 0.79 | CA2 (0.39) | CA2CA12CA14L3MBTL1PTPRC | |
| SCHEMBL3772506 | 0.75 | CA2 (0.37) | CA2CA12CA14L3MBTL1PTPRC | |
| SCHEMBL7442333 | 0.74 | GAA (0.42) | L3MBTL1MEN1GAAKMT2A | |
| SCHEMBL21564883 | 0.73 | CA2 (0.36) | CA2CA12CA14L3MBTL1PTPRC | |
| SCHEMBL2842538 | 0.73 | RECQL (0.41) | CA2CA12CA14L3MBTL1PTPRC | |
| SCHEMBL23894059 | 0.73 | CA2 (0.41) | CA2CA12CA14L3MBTL1PTPRC | |
| SCHEMBL783009 | 0.73 | CA2 (0.41) | CA2CA12CA14L3MBTL1PTPRC | |
| SCHEMBL21625398 | 0.73 | DGAT1 (0.36) | CA2CA12CA14L3MBTL1PTPRC | |
| SCHEMBL7660753 | 0.72 | PTPRC (0.39) | CA2CA12CA14L3MBTL1PTPRC | |
| SCHEMBL7428244 | 0.72 | DGAT1 (0.47) | CA2CA12CA14L3MBTL1PTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109352-B2 | Process for producing optically active amino acid derivatives | KANEKA CORPORATION (JP) | 2006-09-19 | — | — | US | disclosed |
| US-20050143586-A1 | Process for producing optically active amino acid derivatives | KANEKA CORPORATION (JP) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143586-A1 | Process for producing optically active amino acid derivatives | NPEPPS, AAAS, DDC | CA2 286/4885CA12 1984/4885CA14 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.